Personal Account
Gyroscope Therapeutics

Gyroscope Therapeutics

Clinical-stage gene therapy company

Company website
Foundation year

2016

About

Total Funding 

$269.5M

Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.

The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.

Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.

Number of employees

100-250

Headquarters

Stevenage, Herefordshire, United Kingdom


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.